[{"orgOrder":0,"company":"Avion Pharmaceuticals","sponsor":"Aspen Pharmacare Holdings","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"NETHERLANDS","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Conjugated Estrogens","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Avion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Avion Pharmaceuticals \/ Avion Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Avion Pharmaceuticals \/ Avion Pharmaceuticals"},{"orgOrder":0,"company":"Avion Pharmaceuticals","sponsor":"OncoBeta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Rhenium-188","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Avion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Avion Pharmaceuticals \/ OncoBeta","highestDevelopmentStatusID":"12","companyTruncated":"Avion Pharmaceuticals \/ OncoBeta"},{"orgOrder":0,"company":"Avion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Avion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Avion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avion Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Avion Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Traditional treatment methods typically involve surgery, which may have a risk of scarring or loss of function, treatment with Rhenium-SCT (Rhenium-188) employs a non-invasive superficial application of a paste containing ß-emitting particles directly t...

                          Brand Name : Rhenium-SCT

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 23, 2022

                          Lead Product(s) : Rhenium-188

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : OncoBeta

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Avion Pharmaceuticals gets exclusive rights to relaunch Cenestin® in the USA. Cenestin® is the only plant-derived mixture of nine conjugated estrogens indicated for treatment of moderate to severe symptoms of vasomotor, and vulvar and vaginal atrophy d...

                          Brand Name : Cenestin

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 12, 2020

                          Lead Product(s) : Conjugated Estrogens

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved

                          Recipient : Aspen Pharmacare Holdings

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Gloperba (colchicine oral solution) inhibits the Beta tubulin polymerisation, which is indicated for the prophylaxis of gout flares in adults patients.

                          Brand Name : Gloperba

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 27, 2020

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank